Long‐Term Follow‐Up of Lymphatic Malformations in Children Treated with Sildenafil

AbstractBackground/ObjectivesLymphatic malformations (LMs) are challenging to treat. Reports on the benefits of sildenafil for LM management have been mixed. This study evaluated long‐term clinical outcomes of pediatric LM patients after sildenafil treatment.MethodsA retrospective chart review was performed on pediatric LM patients treated with sildenafil in the past 5 years. Patients were also contacted to complete a survey of comprehensive questions about their LM after sildenafil and subsequent interventions.ResultsOf 12 patients identified, 10 (83.3%) participated in the follow‐up survey. The average age was 8 years (range 4–16 yrs), median treatment duration was 9 months, and the average time of follow‐up after sildenafil was 4 years; one patient is still taking sildenafil. Ten patients surveyed (83.3%) reported positive therapeutic response, with improvement in the size and compressibility of their LM during posttreatment clinical visits. Six received additional interventions (four sirolimus, one sclerotherapy, one surgery) after sildenafil was discontinued, with all but one reporting a positive response to subsequent interventions. Minor side effects at the time of sildenafil treatment included mild flushing, dizziness, and transient nausea, but no adverse effects were reported at the long‐term follow‐up.ConclusionThis is the first report of long‐term follow‐up of pediatric LM patients treated with sildenafil. Our findings suggest that sildenafil is beneficial for the symptomatic treatment of LMs. Additional analysis on the role of sildenafil as adjuvant therapy is necessary to optimize the use of this medication in the management of complex LMs.